Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.
Incyte recently announced positive 52-week data from a phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, for the treatment of extensive nonsegmental vitiligo in adult patients. Findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany. The results build upon previously announced data and suggest significant advancements in potential treatment.1
Using the Total Vitiligo Area Scoring Index (T-VASI) for total body depigmentation and the facial Vitiligo Area Scoring Index (F-VASI) for facial depigmentation to measure depigmentation improvements, study results showed:
Secondary end points included:
Incyte’s phase 2b study (NCT04818346) was a randomized, double-blind, placebo-controlled study enrolling 171 adult patients with extensive nonsegmental vitiligo. The primary endpoint was the percentage change from baseline in T-VASI at week 24, and key secondary endpoints included the percentage of patients achieving ≥50% reduction from baseline in the T-VASI T-VASI50 at week 24.
“These 52-week results further support earlier data and reinforce the efficacy profile and potential of povorcitinib as an oral treatment for patients with extensive nonsegmental vitiligo,” said Kurt Brown, MD, vice president and povorcitinib global program head at Incyte, in the news release. “At Incyte, we are deeply committed to addressing unmet needs in the vitiligo community and understanding how this disease can affect patients’ lives. Today’s data highlight exciting progress as we work to bring new potential treatment options to patients living with this immune-mediated skin condition.”